GlobeNewswire Inc. · Sep 15, 2022
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”
CL
NASDAQ · CLBS
Caladrius Biosciences, Inc.
Healthcare · Biotechnology
$0.43
Down-$0.09 (-16.75%)
Updated Aug 15, 2026, 4:59 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.35M
- P/E ratio
- -0.97
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 26.95M
- Avg. volume
- 79.65K
Price performance
CLBS price history
1M range · 0 trading sessions · Daily adjusted prices
CLBS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CLBS news
The latest Smart Investors Daily articles mentioning CLBS.
Stock researchCompany · Overview
CLBS research
Overview
Company profile and research snapshot.
Company profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.59
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 23, 2022 | HC Wainwright & Co. | Buy | — |
| Mar 3, 2021 | Brookline Capital | Buy | — |
| May 14, 2019 | WBB Securities | Speculative Buy | — |
| Mar 23, 2018 | Chardan Capital | Buy | — |
| Mar 7, 2018 | H.C. Wainwright | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 14, 2022
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
All Merger-related proposals approved at the Annual Meeting of Stockholders All Merger-related proposals approved at the Annual Meeting of Stockholders
GlobeNewswire Inc. · Aug 10, 2022
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations
GlobeNewswire Inc. · Aug 4, 2022
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
